Halozyme's subsidiary Halozyme Hypercon signed a global exclusive collaboration and license agreement with Vertex Pharmaceuticals to license Halozyme's Hypercon technology for use in up to three drug targets. Financial terms were not disclosed; the deal represents third-party validation of Halozyme's platform and could be accretive to Halozyme's pipeline value if targets advance.
Halozyme's subsidiary Halozyme Hypercon signed a global exclusive collaboration and license agreement with Vertex Pharmaceuticals to license Halozyme's Hypercon technology for use in up to three drug targets. Financial terms were not disclosed; the deal represents third-party validation of Halozyme's platform and could be accretive to Halozyme's pipeline value if targets advance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
